Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 990.00 125,070 16:35:14
Bid Price Offer Price High Price Low Price Open Price
970.00 990.00 1,005.00 980.00 980.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.30 -9.72 -17.34 736
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:14 O 1,500 973.00 GBX

Maxcyte (MXCT) Latest News

More Maxcyte News
Maxcyte Investors    Maxcyte Takeover Rumours

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
02/3/202110:17Maxcyte: Any molecule, any cell, any scale595
23/11/202009:57CRISPR-
13/7/201613:43MaxCyte (MXCT) Right here, right now: catching the CAR-T wave2

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18:22:36973.001,50014,595.00O
17:15:00970.002,47524,007.50O
17:15:00973.662,97929,005.33O
17:15:00972.002,34922,832.28O
17:15:00980.007,50073,500.00O
View all Maxcyte trades in real-time

Maxcyte (MXCT) Top Chat Posts

DateSubject
02/3/2021
08:20
Maxcyte Daily Update: Maxcyte Inc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 990p.
Maxcyte Inc has a 4 week average price of 660p and a 12 week average price of 442p.
The 1 year high share price is 1,060p while the 1 year low share price is currently 122.50p.
There are currently 74,325,857 shares in issue and the average daily traded volume is 115,161 shares. The market capitalisation of Maxcyte Inc is £735,825,984.30.
15/2/2021
19:17
acuere: If they were obliged to sell at the 650p level, I assume they will have to reduce further seeing as share price nearly 50% higher now. I wonder if they notified Maxcyte today of a further reduction and Mxct realised they hadn’t told the market about Jan 25th notification. If that’s the case I wouldn’t be suprised to see another holdings RNS shortly.
05/2/2021
08:58
someuwin: For those new to the story here, look at all these diseases that MXCT's tech is currently being used with in ongoing clinical trials. Each of these are being developed by, and funded by some of the biggest and best biotech companies in the world. MXCT calls them partners not customers. MXCT is getting revenues now for licenses, milestones, tech rental, sales etc. But as and when any of these drugs come to market MXCT will get significant royalties on sales. That's the BIG driver here - where else can you get exposure to that sort of upside at such a low price? And that's just the trials being done currently. We know that as they enter 2021 their pipeline of new partnerships is the largest they've ever seen!
05/2/2021
08:46
adamb1978: TheTrotsky Agree that with these sort of rises you need to be braced for sharp pullbacks too. However the one thing whic might support it here is the roadshow which supported the recetn placing. That will ahve put MSCT on the radar on a range of US investors, particularly as the company moves to Nasdaq. A bunch of those will realise the revaluation which will occur and will therefore be picking up shares now, partly for arbitrage and partly as a long-term holding in a company which the were previously unaware of. Its crazy when a share price goes up almost the same as your entire in-price in 1 day! Adam
04/2/2021
16:46
tictac: Would anyone care to suggest what the share price should be if it had a Nasdaq valuation?
04/2/2021
09:40
2theduke: It's interesting that the fund raise would have been enough for trials on the CARMA product. It really shows the value now assigned to the core proposition, it's all become much more viable since the CX0001 outcome in December. Without doubt this fund raise was for US investors and liquidity in the stock. If you are querying the need for the capital, there is a further point of what are they planning on doing with a US placement that will probably be an absolute minimum of $1bn valuation. The $1bn excludes ANY progress in partner clinical trials and the likely sizable cash injection due from the CARMA out license (which no one seems to be referencing). As always there are downside risks, and this new liquidity could be used to keep the price sensible to support a US listing, with the UK as illiquid as it is, you can see the impact just us have on moving the price (and spread). Finally re the point on the takeover, well that really shows the value doesnt it? If CX0001 alone is $50m a year in royalities and MXCT as a whole is valued at £600m, well then it's a no brainer as a target (barring any change of control clauses in agreements, which could make sense as MXCT supply most of the co's in the sector). Enjoy the 14:00 show when the US comes online.
03/2/2021
16:54
adamb1978: Important things are that (i) its been done at a premium to the share price and (ii) its only a small portion of the share cap. COnfirms therefore that management has their heads screwed on correctly!
21/1/2021
17:27
74tom: There are none as blind as those who will not see... Quite how you can be seriously talking down MXCT at this point is beyond me. I'd say the extremely positive Crispr/Vertex news in December has increased the likelihood of success considerably, hence the rising share price. Next read outs will be key of course, but it would be a big surprise if the first 8 patients treated were all practically cured by chance. Exhibit 8 of this excellent research note from May 2020 exemplifies the 3-5 year (from today's date) revenue potential. It appears to suggest that milestone payments represent around 10-20% of the commercial licensing value of a single product, so the $950m pre clinical milestone payments could represent between $5-10b of commercial phase revenues. Extraordinary. https://www.trinitydelta.org/wp-content/uploads/2020/05/MaxCyte-Outlook-200526.pdf
20/1/2021
07:28
multibagger: Trading Update: Mixed bag in my view.. I think the market was hoping for more than +21% revenue growth and reading between the lines, looks like CARMA could not be sold at a price they were hoping for/able to accept. However clinical partnerships, licences and pre-commercialisation potential revenue has grown to $950m and NASDAQ dual listing on schedule for 2021. I am still very confident about medium to longer term growth and revenue prospects, but won't be surprised to see a pull back in share price today in the range of 50-60p or more. Good luck all ! DoI: I hold a fair few and won't be selling :)
11/1/2021
11:12
acuere: As an indication of the lack of awareness of Mxct look at the Lse BB. Only 6 posts since July when share price was 217p. And none at all since 24th Nov. Quiet BBs always a good sign for me.
09/12/2020
20:28
gsbmba99: You are attributing the movement in the share price to the EDIT-301 presentation. I would argue share price movement is more likely to do with EDIT-201 (healthy donor NK cells) developments which was the subject of two presentations at ASH. See also recent performance of NKTX and FATE. I hope EDIT-301 does well but it's 2+ years behind CTX-001 and not obviously differentiated/better. Or it could be a relief rally of sorts following a flat performance YTD in a sector that's been performing very well. The good news is we'll never know. The use of MXCT technology in EDIT-301 was announced (via RNS) on 7 October 2019. "We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
Maxcyte share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210302 21:14:47